Browse evidence-based analysis of health-related claims and assertions
More visceral fat in psoriasis patients is linked to worse cholesterol profiles, increasing heart disease risk.
Correlational
People with psoriasis or psoriatic arthritis have slightly more fat under the skin than healthy people with similar body weight, though this difference is not statistically significant.
Descriptive
People with psoriasis or psoriatic arthritis have a higher proportion of visceral fat within their abdominal cavity compared to healthy individuals with similar body weight.
Larger body size in psoriasis patients is strongly linked to worse disease control, as measured by standard disease activity scores.
People with psoriasis or psoriatic arthritis who have larger body sizes tend to report more difficulty with daily activities, as measured by standard health questionnaires.
More visceral fat in psoriasis patients is linked to lower levels of a protective hormone called adiponectin, which helps regulate metabolism.
More visceral fat in people with psoriasis is linked to higher insulin resistance, a key factor in diabetes risk, based on statistical analysis of the data.
People with psoriasis or psoriatic arthritis have a higher proportion of dangerous belly fat compared to safe fat under the skin, even when their overall weight is similar to healthy people.
People with psoriasis or psoriatic arthritis have about 6% more fat around their internal organs than people without these conditions, even when they have the same body weight.
After 6 months of oral semaglutide treatment, 32 people with type 2 diabetes had lower blood pressure, with an average drop of about 5%.
Quantitative
After 6 months of oral semaglutide treatment, 32 people with type 2 diabetes had lower liver enzyme levels, indicating improved liver health.
On average, 32 people with type 2 diabetes lost about 5% of their body weight after taking oral semaglutide for 6 months.
After 3 months of oral semaglutide treatment, 32 people with type 2 diabetes had a 16% lower score on a test for fatty liver disease.
After 3 months of taking oral semaglutide, 32 people with type 2 diabetes saw a better balance between muscle mass and belly fat, which improved further by 6 months but wasn't statistically significant.
Half of the 32 people with type 2 diabetes who took oral semaglutide for 6 months lost at least 5% of their body weight.
Taking oral semaglutide for 6 months helped lower blood sugar levels in 32 people with type 2 diabetes, reducing their HbA1c by about 9% on average.
In a group of 32 people with type 2 diabetes, taking oral semaglutide for 6 months led to a noticeable drop in body fat, with an average loss of about 17.6% of their initial fat mass.
Among HIV patients with high liver enzymes, 35% of those who lost at least 8% visceral fat from the drug had their ALT levels return to normal after six months, compared to 18% of those who didn't lose much fat.
HIV patients with belly fat and high liver enzymes who lost at least 8% of their visceral fat from the drug saw their ALT drop by about 9 points (18%) and AST by 4 points (10%) after six months of treatment.
HIV patients with high liver enzymes who lost visceral fat from the drug kept their liver enzyme levels improved for a full year even after stopping the drug and some fat coming back.
Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzyme levels.
For HIV patients with belly fat and high liver enzymes, taking a placebo even if they lost visceral fat didn't help lower their liver enzyme levels, unlike those taking the actual drug.
HIV patients with high liver enzymes who lost at least 8% of their visceral fat from the drug were 2.5 times more likely to have their ALT levels return to normal compared to those who didn't lose much fat.
In people with HIV and belly fat, having more visceral fat was linked to higher levels of a liver enzyme called ALT, which suggests a connection between belly fat and liver health.